Aptargroup, Inc. (ATR) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $1.52 vs ~$1.47 consensus
AptarGroup’s Q3 earnings beat consensus on sales and adjusted EPS, but Russia deconsolidation and weaker margins complicate the growth story.
AptarGroup is entering a CEO transition while trying to turn strong pharmaceutical and dispensing demand into more consistent execution; the current operating picture is strongest in Pharma and Closures, while Beauty and parts of North American operations remain the drag.
The quarter beat the published bar. Adjusted EPS was $1.52 versus a published consensus of about $1.47, while sales reached $1.019 billion versus roughly $981 million expected. Revenue growth was broad, with reported sales up 2% in Pharma, 9% in Beauty, and 11% in Closures; core sales growth was 1%, 8%, and 11%, respectively. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net sales (Financial Statements) | $1,019.1M (+6.0%) | $961.1M | ~$980.8M |
| Adjusted diluted EPS (Adjusted EPS reconciliation) | $1.52 | $1.62 | ~$1.47 |
| Adjusted EBITDA (Segment results) | $217.2M (-2.4%) | $222.6M | |
| Free cash flow (Free Cash Flow) | $98.6M (-13.7%) | $114.3M |
The quality of the beat is mixed. The revenue upside came with lower consolidated adjusted EBITDA margin, down to 21.3% from 23.2%, as Pharma absorbed emergency-medicine destocking, Beauty faced unfavorable mix and North American operating issues, and Closures experienced input-cost pass-through dilution. Pharma’s 36.4% margin remains above its long-term target, but the other segments show that growth is not yet translating cleanly into profit. 〔1〕
A new Russia charge makes reported earnings look much worse than the underlying quarter. Aptar recorded a $58.0 million deconsolidation loss and said the total after-tax impact was $60.4 million, or $0.94 per diluted share, after losing control of its Russian subsidiary. That pushed reported diluted EPS down to $0.51 from $1.92, but the charge is non-recurring; the more relevant operating signal is adjusted EPS of $1.52, down from $1.62 despite the sales beat.
The outlook is constructive but not a fresh full-year upgrade. Aptar expects fourth-quarter adjusted EPS of $1.39–$1.47, supported by Pharma growth after emergency-medicine destocking ends and continued Closures momentum, while Beauty remains an execution project. The filing does not provide a new full-year adjusted EPS target, so the main surprise is the quarterly beat rather than a major reset of the company’s longer-term earnings trajectory.
Bottom line: Aptar delivered a real Q3 beat on sales and adjusted EPS, led by Pharma and Closures. But weaker margins, softer underlying adjusted profit versus last year, and the Russia loss keep this from reading as a clean acceleration story.
Q3 earnings call, October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!